Meyka Pro banner
Lobe Sciences Ltd.

Lobe Sciences Ltd. Fundamental Analysis (CNQ: LOBE.CN)

LOBE.CNCNQ
HealthcareBiotechnology
$0.07
$0.010(12.50%)
Canadian Market opens in 14h 43m

Lobe Sciences Ltd. Fundamental Analysis (CNQ: LOBE.CN)

Lobe Sciences Ltd. (CNQ: LOBE.CN) shows weak financial fundamentals with a PE ratio of -3.40, profit margin of 0.00%, and ROE of -3.39%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position26.78%
PEG Ratio-0.08
Current Ratio2.38

Areas of Concern

ROE-3.39%
Operating Margin0.00%
We analyze LOBE.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -388.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-388.2/100

We analyze LOBE.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

LOBE.CN struggles to generate sufficient returns from assets.

ROA > 10%
-93.41%

Valuation Score

Excellent

LOBE.CN trades at attractive valuation levels.

PE < 25
-3.40
PEG Ratio < 2
-0.08

Growth Score

Weak

LOBE.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

LOBE.CN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.18
Current Ratio > 1
2.38

Profitability Score

Weak

LOBE.CN struggles to sustain strong margins.

ROE > 15%
-338.76%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is LOBE.CN Expensive or Cheap?

P/E Ratio

LOBE.CN trades at -3.40 times earnings. This suggests potential undervaluation.

-3.40

PEG Ratio

When adjusting for growth, LOBE.CN's PEG of -0.08 indicates potential undervaluation.

-0.08

Price to Book

The market values Lobe Sciences Ltd. at 10.31 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

10.31

EV/EBITDA

Enterprise value stands at -3.06 times EBITDA. This is generally considered low.

-3.06

How Well Does LOBE.CN Make Money?

Net Profit Margin

For every $100 in sales, Lobe Sciences Ltd. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-3.39 in profit for every $100 of shareholder equity.

-3.39%

ROA

Lobe Sciences Ltd. generates $-93.41 in profit for every $100 in assets, demonstrating efficient asset deployment.

-93.41%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

LOBE.CN converts -18.83% of its market value into free cash.

-18.83%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.40

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.08

vs 25 benchmark

P/B Ratio

Price to book value ratio

10.31

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.18

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.38

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-3.39

vs 25 benchmark

ROA

Return on assets percentage

-0.93

vs 25 benchmark

ROCE

Return on capital employed

-2.14

vs 25 benchmark

How LOBE.CN Stacks Against Its Sector Peers

MetricLOBE.CN ValueSector AveragePerformance
P/E Ratio-3.4032.02 Better (Cheaper)
ROE-338.76%569.00% Weak
Net Margin0.00%29948.00% Weak
Debt/Equity0.180.53 Strong (Low Leverage)
Current Ratio2.385.67 Strong Liquidity
ROA-93.41%-98.00% (disorted) Weak

LOBE.CN outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Lobe Sciences Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ